The transcriptomic analysis also revealed that GZ17-6.02 treatment results in suppression of several genes implicated in glioblastoma growth and invasion, such as EGR1, ASCL1, CD109, ABCG2, and CDH5. This evidence concerns the gene CD109 and glioblastoma.